Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis.

Yushiro Endo,Shoichi Fukui,Kunihiko Umekita,Takahisa Suzuki,Junya Miyamoto,Shimpei Morimoto,Toshimasa Shimizu,Tomohiro Koga,Shin-ya Kawashiri,Naoki Iwamoto,Kunihiro Ichinose,Mami Tamai,Tomoki Origuchi,Akitomo Okada,Keita Fujikawa,Akinari Mizokami,Naoki Matsuoka,Toshiyuki Aramaki,Yukitaka Ueki,Katsumi Eguchi,Yumi Kariya,Yayoi Hashiba,Toshihiko Hidaka,Akihiko Okayama,Atsushi Kawakami,Hideki Nakamura

Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis.

2020

Our previous study showed that the effectiveness of tumor necrosis factor (TNF) inhibitors was attenuated in anti-human T-cell leukemia virus type 1 (HTLV-1) antibody-positive patients with rheumat...

Keywords:

Tocilizumab
Antibody
Leukemia
Rheumatoid arthritis
Human T cell leukemia virus
Tumor necrosis factor alpha
Cancer research
Abatacept
Medicine
virus type

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations